Brii Biosciences, Vir Biotechnology and VBI Vaccines Announce Initiation of Phase II Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

Brii Biosciences, Vir Biotechnology, Inc., and VBI Vaccines Inc. announced that the first patient had been dosed in a Phase II clinical trial evaluating BRII-835 (VIR-2218), an investigational small interfering ribonucleic acid targeting hepatitis B virus, in combination with BRII-179, an investigational HBV immunotherapeutic, for the treatment of chronic HBV infection.
[Brii Biosciences, Vir Biotechnology, Inc., and VBI Vaccines, Inc. (GLOBENEWS WIRE)]
Press Release
Bookmark

No account yet? Register

0
Share

Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase I Proof-of-Concept Study

Aligos Therapeutics, Inc. announced that the company has started dosing in the first cohort of chronic hepatitis B patients in the ongoing ALG-000184-201 study.
[Aligos Therapeutics, Inc. (GLOBENEWS WIRE)]
Press Release
Bookmark

No account yet? Register

0
Share

Chitinase 3-Like 1 Is a Profibrogenic Factor Overexpressed in the Aging Liver and in Patients with Liver Cirrhosis

Scientists hypothesized that the pace of fibrosis progression might reflect changes in gene expression within the aging liver.
[Proceedings of the National Academy of Sciences of the United States of America]
Nishimura, N., Battista, D. D., McGivern, D. R., Engle, R. E., Tice, A., Fares-Gusmao, R., Kabat, J., Pomerenke, A., Nguyen, H., Sato, S., Bock, K. W., Moore, I. N., Kleiner, D. E., Zamboni, F., Alter, H. J., Govindarajan, S., & Farci, P. (2021). Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis. Proceedings of the National Academy of Sciences, 118(17). https://doi.org/10.1073/pnas.2019633118 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Long Non-coding RNA Muskelin 1 Antisense RNA (MKLN1-AS) Is a Potential Diagnostic and Prognostic Biomarker and Therapeutic Target for Hepatocellular Carcinoma

Researchers investigated the detailed biological role of muskelin 1 antisense RNA (MKLN1)-AS and Yes-associated transcriptional regulator 1 (YAP1)-related mechanisms.
[Experimental and Molecular Pathology]
Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) is a potential diagnostic and prognostic biomarker and therapeutic target for hepatocellular carcinoma. (2021). Experimental and Molecular Pathology, 104638. https://doi.org/10.1016/j.yexmp.2021.104638 Cite
Abstract
Bookmark

No account yet? Register

0
Share

The Interplay of microRNAs and Transcription Factors in Autophagy Regulation in Nonalcoholic Fatty Liver Disease

we summarize the microRNAs and transcription factors that regulate the autophagy pathway in nonalcoholic fatty liver disease.
[Experimental and Molecular Medicine]
Kim, Y., Lee, D.-H., Park, S.-H., Jeon, T.-I., & Jung, C. H. (2021). The interplay of microRNAs and transcription factors in autophagy regulation in nonalcoholic fatty liver disease. Experimental & Molecular Medicine, 1–12. https://doi.org/10.1038/s12276-021-00611-0 Cite
Full Article
Bookmark

No account yet? Register

0
Share

VBI Vaccines Announces Phase Ib/IIa Data and Progress of Hepatitis B Immunotherapeutic Candidate

VBI Vaccines. Inc., announced data and next steps from the high-dose cohort of its Phase Ib/IIa clinical study of VBI-2601 (BRII-179), the company’s hepatitis B immunotherapeutic candidate, in chronically-infected hepatitis B patients.
[VBI Vaccines, Inc. (businesswire)]
Press Release
Bookmark

No account yet? Register

0
Share

VBI Vaccines Announces Phase Ib/IIa Data and Progress of Hepatitis B Immunotherapeutic Candidate

VBI Vaccines Inc. announced data and next steps from the high-dose cohort of its Phase Ib/IIa clinical study of VBI-2601, the company’s hepatitis B immunotherapeutic candidate, in chronically-infected hepatitis B patients.
[VBI Vaccines Inc. (BusinessWire, Inc)]
Press Release
Bookmark

No account yet? Register

0
Share

Does the Epithelial Barrier Hypothesis Explain the Increase in Allergy, Autoimmunity and Other Chronic Conditions?

Scientists discuss how the immune responses to dysbiotic microbiota that cross the damaged barrier may be involved in the development of allergic and autoimmune diseases.
[Nature Reviews Immunology]
Akdis, C. A. (2021). Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nature Reviews Immunology, 1–13. https://doi.org/10.1038/s41577-021-00538-7 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Synergistic Effect of the TLR5 Agonist CBLB502 and Its Downstream Effector IL-22 against Liver Injury

Scientists investigated the protective mechanism of CBLB502 in the liver using models of ischemia-reperfusion injury and concanavalin A induced immuno-hepatitis.
[Cell Death & Disease]
Full Article
Bookmark

No account yet? Register

0
Share

Clearance of Pegylated Interferon by Kupffer Cells Limits NK Cell Activation and Therapy Response of Patients with HBV Infection

Scientists found that patients with early natural killer cell activation after PEG–IFN-α injection experienced greater liver inflammation, lysis of HBV-infected hepatocytes, and hepatitis B surface antigen decline than those without.
[Science Translational Medicine]
Nishio, A., Bolte, F. J., Takeda, K., Park, N., Yu, Z.-X., Park, H., Valdez, K., Ghany, M. G., & Rehermann, B. (2021). Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection. Science Translational Medicine, 13(587). https://doi.org/10.1126/scitranslmed.aba6322 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Tumor Necrosis Factor‐α‐Induced Protein 8‐like 2 Alleviates Nonalcoholic Fatty Liver Disease via Suppressing TAK1 Activation

Tumor necrosis factor‐α‐induced protein 8‐like 2 suppressed nonalcoholic fatty liver disease (NAFLD) advancement by blocking transforming growth factor‐beta‐activated kinase 1‐c‐Jun NH2‐terminal kinase/p38 pathway and was a promising target molecule for NAFLD therapy.
[Hepatology]
Abstract
Bookmark

No account yet? Register

0
Share
Share